Literature DB >> 19460579

Acute leukemia in adolescents and young adults.

Anjali S Advani1, Stephen P Hunger, Alan K Burnett.   

Abstract

In many areas of medicine adolescents are regarded as a discrete group with specific therapeutic, psychological, educational, and resource needs. In the treatment of acute leukemia age is a predictor of response. Thus, in acute lymphoblastic leukemia (ALL) there is a clearly poorer treatment outcome after puberty, while in acute myeloid leukaemia (AML), which is more common in older adults, age is a continuous variable with poorer outcomes in each successive decade. Much is known about other prognostic factors and their relative incidence in each age stratum. Although there is some segregation of favorable factors with relative youth, age usually remains an independent factor with respect to prognosis. Adolescents may be included in pediatric or adult-oriented treatment protocols. Here we discuss the outcome of acute leukemia in adolescents and young adults, particularly with respect to whether they respond similarly to children or other adults.

Entities:  

Mesh:

Year:  2009        PMID: 19460579     DOI: 10.1053/j.seminoncol.2009.03.007

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  14 in total

1.  Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.

Authors:  Simona Lapusan; Maria B Vidriales; Xavier Thomas; Stephane de Botton; Anne Vekhoff; Ruoping Tang; Charles Dumontet; Rodica Morariu-Zamfir; John M Lambert; Marie-Laure Ozoux; Philippe Poncelet; Jesus F San Miguel; Ollivier Legrand; Daniel J DeAngelo; Francis J Giles; Jean-Pierre Marie
Journal:  Invest New Drugs       Date:  2011-04-26       Impact factor: 3.850

Review 2.  Genomic profiling of B-progenitor acute lymphoblastic leukemia.

Authors:  Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2011-11-06       Impact factor: 3.020

3.  Allogeneic hematopoietic stem cell transplantation for patients with acute leukemia.

Authors:  Yan Chen; Yajing Xu; Gan Fu; Yi Liu; Jie Peng; Bin Fu; Xiaoyu Yuan; Hongya Xin; Yan Zhu; Qun He; Dengshu Wu; Yigang Shu; Xiaolin Li; Xielan Zhao; Fangping Chen
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

4.  FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Authors:  Kelly J Norsworthy; Chia-Wen Ko; Jee Eun Lee; Jiang Liu; Christy S John; Donna Przepiorka; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2018-04-12

5.  Adolescent and young adult cancer survival.

Authors:  Denise Riedel Lewis; Nita L Seibel; Ashley Wilder Smith; Margaret R Stedman
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

6.  Comprehensive assessment of the association between DNA repair gene XRCC3 Thr241Met polymorphism and leukemia risk.

Authors:  Lingyan Qin; Xu Chen; Ping Li; Zheng Yang; Wuning Mo
Journal:  Tumour Biol       Date:  2013-11-06

Review 7.  Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.

Authors:  James V Tricoli; Donald G Blair; Carey K Anders; W Archie Bleyer; Lisa A Boardman; Javed Khan; Shivaani Kummar; Brandon Hayes-Lattin; Stephen P Hunger; Melinda Merchant; Nita L Seibel; Magdalena Thurin; Cheryl L Willman
Journal:  Cancer       Date:  2016-02-05       Impact factor: 6.860

8.  Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Farhad Ravandi; Graciela M Nogueras-Gonzalez; Xuelin Huang; Susan O'Brien; William Wierda; Guillermo Garcia-Manero; Deborah Thomas; Sherry Pierce; Srdan Verstovsek; Gautam Borthakur; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-01-05

9.  Association between CYP1A1 Ile462Val variation and acute leukemia risk: meta-analyses including 2164 cases and 4160 controls.

Authors:  Wenlei Zhuo; Liang Zhang; Bo Zhu; Zhiqun Qiu; Zhengtang Chen
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

Review 10.  Far from Health: The Bone Marrow Microenvironment in AML, A Leukemia Supportive Shelter.

Authors:  Stephanie Sendker; Katharina Waack; Dirk Reinhardt
Journal:  Children (Basel)       Date:  2021-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.